€7.5 Billion for Biotech, Biomedicines, and Health Innovation
France 2030 allocates €7.5 billion to the health and biotech sector with a clear objective: make France a top-3 global producer of biomedicines and medical devices. France already ranks 2nd in the EU for biopharmaceutical production, with 47 biomedicines manufactured domestically.
Biotherapy and Gene Therapy
France 2030 funds biomanufacturing capacity expansion across the country. Sanofi invested €1.6 billion in its Neuville-sur-Saône biologics facility. Servier and Ipsen are expanding domestic production. The Genopole cluster in Évry houses 80+ biotech companies, making it France’s premier life science hub.
Key Health Unicorns and Champions
| Company | Valuation | Focus |
|---|---|---|
| Doctolib | €6.4B | Healthcare appointments, 80M patients |
| Alan | €4.5B | Digital health insurance |
| Owkin | $1B | Federated learning drug discovery |
| Dental Monitoring | €500M+ | AI dental diagnostics |
Clinical Trials Hub
France conducts 4,000+ clinical trials annually, ranking 3rd in Europe. France 2030 funds digital health infrastructure including AI-powered patient recruitment, electronic health records interoperability, and the Health Data Hub (120M+ anonymized patient records for research). The goal: make France the European hub for clinical trial outsourcing.
Medical Devices and MedTech
France’s medtech sector employs 90,000+ workers across 1,500 companies. France 2030 supports surgical robotics, connected medical devices, and AI diagnostics. Key clusters: Paris-Saclay, Lyon (bioMerieux, Sanofi Pasteur), and Strasbourg (IRCAD surgical robotics center).